A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers

Trial Profile

A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs CBLC 137 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Cleveland BioLabs; Incuron
  • Most Recent Events

    • 17 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 11 Oct 2016 Status changed from planning to not yet recruiting.
    • 09 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top